haemonetics corp. - HAE

HAE

Close Chg Chg %
102.84 -0.46 -0.45%

Open Market

102.38

-0.46 (0.45%)

Volume: 71.97K

Last Updated:

Sep 9, 2026, 11:04 AM EDT

Company Overview: haemonetics corp. - HAE

HAE Key Data

Open

$102.50

Day Range

100.57 - 102.70

52 Week Range

47.32 - 109.57

Market Cap

$4.68B

Shares Outstanding

45.50M

Public Float

44.64M

Beta

0.54

Rev. Per Employee

N/A

P/E Ratio

50.20

EPS

$2.06

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

750.68K

 

HAE Performance

1 Week
 
-0.08%
 
1 Month
 
17.08%
 
3 Months
 
31.51%
 
1 Year
 
97.01%
 
5 Years
 
52.42%
 

HAE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About haemonetics corp. - HAE

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

HAE At a Glance

Haemonetics Corp.
125 Summer Street
Boston, Massachusetts 02110
Phone 1-781-848-7100 Revenue 1.33B
Industry Medical Specialties Net Income 97.31M
Sector Health Technology Employees 3,009
Fiscal Year-end 03 / 2027
View SEC Filings

HAE Valuation

P/E Current 50.20
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 26.298
Price to Sales Ratio 1.918
Price to Book Ratio 3.071
Price to Cash Flow Ratio 8.73
Enterprise Value to EBITDA 10.07
Enterprise Value to Sales 2.69
Total Debt to Enterprise Value 0.355

HAE Efficiency

Revenue/Employee 443,345.63
Income Per Employee 32,338.983
Receivables Turnover 6.152
Total Asset Turnover 0.55

HAE Liquidity

Current Ratio 2.954
Quick Ratio 1.87
Cash Ratio 0.869

HAE Profitability

Gross Margin 55.70
Operating Margin 18.337
Pretax Margin 9.597
Net Margin 7.294
Return on Assets 4.015
Return on Equity 12.034
Return on Total Capital 4.699
Return on Invested Capital 5.056

HAE Capital Structure

Total Debt to Total Equity 160.076
Total Debt to Total Capital 61.55
Total Debt to Total Assets 53.204
Long-Term Debt to Equity 158.286
Long-Term Debt to Total Capital 60.861
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Haemonetics Corp. - HAE

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
1.17B 1.31B 1.36B 1.33B
Sales Growth
+17.67% +12.01% +3.95% -1.97%
Cost of Goods Sold (COGS) incl D&A
578.43M 632.52M 645.50M 590.97M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
93.31M 97.22M 115.59M 111.72M
Depreciation
51.21M 55.81M 59.99M 67.72M
Amortization of Intangibles
42.10M 41.40M 55.60M 44.00M
COGS Growth
+12.31% +9.35% +2.05% -8.45%
Gross Income
590.23M 676.54M 715.33M 743.06M
Gross Income Growth
+23.44% +14.62% +5.73% +3.88%
Gross Profit Margin
+50.51% +51.68% +52.57% +55.70%
2023 2024 2025 2026 5-year trend
SG&A Expense
423.03M 468.40M 492.99M 498.44M
Research & Development
49.08M 52.23M 61.13M 58.80M
Other SG&A
373.95M 416.17M 431.85M 439.64M
SGA Growth
+15.30% +10.72% +5.25% +1.11%
Other Operating Expense
- - - -
-
Unusual Expense
9.19M 43.75M 2.13M 90.36M
EBIT after Unusual Expense
158.01M 164.39M 220.22M 154.26M
Non Operating Income/Expense
(737.00K) 3.97M 1.74M 5.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
15.88M 16.50M 9.89M 26.23M
Interest Expense Growth
-14.20% +3.91% -40.06% +165.32%
Gross Interest Expense
15.88M 16.50M 9.89M 26.23M
Interest Capitalized
- - - -
-
Pretax Income
141.40M 151.87M 212.07M 128.03M
Pretax Income Growth
+122.23% +7.40% +39.64% -39.63%
Pretax Margin
+12.10% +11.60% +15.58% +9.60%
Income Tax
26.00M 34.31M 44.39M 30.72M
Income Tax - Current - Domestic
11.29M 35.65M 37.93M 44.87M
Income Tax - Current - Foreign
8.94M 9.53M 12.09M 12.25M
Income Tax - Deferred - Domestic
6.62M (4.03M) (4.78M) (21.14M)
Income Tax - Deferred - Foreign
(843.00K) (6.84M) (842.00K) (5.27M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
115.40M 117.56M 167.68M 97.31M
Minority Interest Expense
- - - -
-
Net Income
115.40M 117.56M 167.68M 97.31M
Net Income Growth
+166.05% +1.87% +42.64% -41.97%
Net Margin Growth
+9.87% +8.98% +12.32% +7.29%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
115.40M 117.56M 167.68M 97.31M
Preferred Dividends
- - - -
-
Net Income Available to Common
115.40M 117.56M 167.68M 97.31M
EPS (Basic)
2.2724 2.3184 3.3316 2.0625
EPS (Basic) Growth
+167.44% +2.02% +43.70% -38.09%
Basic Shares Outstanding
50.78M 50.71M 50.33M 47.18M
EPS (Diluted)
2.2443 2.2872 3.3053 2.0549
EPS (Diluted) Growth
+165.72% +1.91% +44.51% -37.83%
Diluted Shares Outstanding
51.42M 51.40M 50.73M 47.35M
EBITDA
260.51M 305.35M 337.93M 356.34M
EBITDA Growth
+24.65% +17.22% +10.67% +5.45%
EBITDA Margin
+22.29% +23.33% +24.83% +26.71%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 106.40
Number of Ratings 12 Current Quarters Estimate 1.29
FY Report Date 09 / 2026 Current Year's Estimate 5.297
Last Quarter’s Earnings 1.14 Median PE on CY Estimate N/A
Year Ago Earnings 4.96 Next Fiscal Year Estimate 5.739
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 11 11
Mean Estimate 1.29 1.35 5.30 5.74
High Estimates 1.37 1.43 5.36 5.86
Low Estimate 1.21 1.25 5.25 5.47
Coefficient of Variance 4.39 4.49 0.66 2.04

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 2 2 2
HOLD 4 4 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Haemonetics Corp. in the News